Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males
Latest Information Update: 19 Feb 2014
At a glance
- Drugs ODM 102 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Orion
- 19 Feb 2014 New trial record